SCHEMBL2296469

SCHEMBL2296469

COC(=O)c1ccccc1NC(=O)c1ccc(OCc2c(F)cccc2Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
SENP7 Q9BQF6 2/20 0.55
CASP3 P42574 1/20 0.55
TAAR1 Q96RJ0 1/20 0.55
KDM4E B2RXH2 5/20 0.54
HPGD P15428 4/20 0.54
ALDH1A1 P00352 2/20 0.54
ELANE P08246 1/20 0.53
PRTN3 P24158 1/20 0.53
APOBEC3A P31941 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
MAPT P10636 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10395976 0.84 NR1H4 (0.56) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL2291399 0.84 MAOA (0.60) TSHRCYP1A2CYP2D6CYP2C19NPC1
SCHEMBL2291513 0.79 KDM4E (0.69) TSHRCYP1A2CYP2D6CYP2C19NPC1
SCHEMBL365285 0.77 SCN9A (0.52) RAB9ASMN1; SMN2KDM4EHPGDALDH1A1
SCHEMBL6338190 0.76 KDM4E (0.66) TSHRCYP1A2CYP2D6CYP2C19NPC1
SCHEMBL11045073 0.75 F10 (0.77) TSHRCYP1A2CYP2D6CYP2C19NPC1
SCHEMBL4459274 0.75 TSHR (1.00) TSHRCYP1A2CYP2D6CYP2C19NPC1
SCHEMBL29378181 0.75 TSHR (1.00) TSHRCYP1A2CYP2D6CYP2C19NPC1
SCHEMBL10396460 0.75 NR1H4 (0.62) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL6687945 0.75 MAPT (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 TSHR 585/4885CYP1A2 159/4885CYP2D6 205/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 TSHR 684/4885CYP1A2 210/4885CYP2D6 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.